---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-21-008125"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2021-07-22T23:59:59+00:00"
generated_at: "2026-06-30T03:15:26.980284+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# VistaGen Therapeutics appoints Maggie FitzPatrick to board, replacing retiring director Brian Underdown

## Summary
- Dr. Brian J. Underdown retired from VistaGen's board and all committees, effective July 21, 2021, with no disagreement.
- Maggie FitzPatrick appointed as independent director; she is a former chief corporate affairs officer at Exelon and J&J.
- Mary L. Rotunno appointed Chair of Corporate Governance and Nominating Committee and member of Audit Committee.
- Jerry B. Gin appointed Chair of Compensation Committee; FitzPatrick also named to Corporate Governance and Nominating Committee.

## SEC filing metadata
- accession: 0001654954-21-008125
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2021-07-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000165495421008125/0001654954-21-008125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000165495421008125/vtgn8k_july212021.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-21-008125
- JSON: https://secwatch.observer/filing/0001654954-21-008125.json
- Plain text: https://secwatch.observer/filing/0001654954-21-008125.txt

## Key facts
- Executive change
  Brian J. Underdown retired as Director at Vistagen Therapeutics, Inc..
  - Action: retired
  - Role: Director
  source text: Dr. Brian J. Underdown notified the Board of Directors (the “ Board ”) of VistaGen Therapeutics, Inc. (the “ Company ”) of his retirement from the Board and all Board committees, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000165495421008125/0001654954-21-008125-index.htm
- Executive change
  Margaret M. FitzPatrick was appointed as Director at Vistagen Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board appointed Margaret M. FitzPatrick to serve on the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000165495421008125/0001654954-21-008125-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.